Saltar al contenido
Merck

Human papillomavirus type 16 E7 oncoprotein mediates CCNA1 promoter methylation.

Cancer science (2015-08-08)
Kanwalat Chalertpet, Watcharapong Pakdeechaidan, Vyomesh Patel, Apiwat Mutirangura, Pattamawadee Yanatatsaneejit
RESUMEN

Human papillomavirus (HPV) oncoproteins drive distinctive promoter methylation patterns in cancer. However, the underlying mechanism remains to be elucidated. Cyclin A1 (CCNA1) promoter methylation is strongly associated with HPV-associated cancer. CCNA1 methylation is found in HPV-associated cervical cancers, as well as in head and neck squamous cell cancer. Numerous pieces of evidence suggest that E7 may drive CCNA1 methylation. First, the CCNA1 promoter is methylated in HPV-positive epithelial lesions after transformation. Second, the CCNA1 promoter is methylated at a high level when HPV is integrated into the human genome. Finally, E7 has been shown to interact with DNA methyltransferase 1 (Dnmt1). Here, we sought to determine the mechanism by which E7 increases methylation in cervical cancer by using CCNA1 as a gene model. We investigated whether E7 induces CCNA1 promoter methylation, resulting in the loss of expression. Using both E7 knockdown and overexpression approaches in SiHa and C33a cells, our data showed that CCNA1 promoter methylation decreases with a corresponding increase in expression in E7 siRNA-transfected cells. By contrast, CCNA1 promoter methylation was augmented with a corresponding reduction in expression in E7-overexpressing cells. To confirm whether the binding of the E7-Dnmt1 complex to the CCNA1 promoter induced methylation and loss of expression, ChIP assays were carried out in E7-, del CR3-E7 and vector control-overexpressing C33a cells. The data showed that E7 induced CCNA1 methylation by forming a complex with Dnmt1 at the CCNA1 promoter, resulting in the subsequent reduction of expression in cancers. It is interesting to further explore the genome-wide mechanism of E7 oncoprotein-mediated DNA methylation.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Dodecilsulfatosódico, BioReagent, suitable for electrophoresis, for molecular biology, ≥98.5% (GC)
Sigma-Aldrich
Dodecilsulfatosódico, ≥99.0% (GC), dust-free pellets
Sigma-Aldrich
Sodium dodecyl sulfate solution, BioUltra, for molecular biology, 10% in H2O
Sigma-Aldrich
Acrilamida, suitable for electrophoresis, ≥99%
Sigma-Aldrich
Dodecilsulfatosódico, ACS reagent, ≥99.0%
Sigma-Aldrich
Sodium dodecyl sulfate solution, BioUltra, for molecular biology, 20% in H2O
Sigma-Aldrich
Dodecilsulfatosódico, ReagentPlus®, ≥98.5% (GC)
Sigma-Aldrich
Acrilamida, for molecular biology, ≥99% (HPLC)
Sigma-Aldrich
Dodecilsulfatosódico, BioUltra, for molecular biology, ≥99.0% (GC)
Sigma-Aldrich
Acrylamide solution, 40%, suitable for electrophoresis, sterile-filtered
Sigma-Aldrich
Acrilamida, suitable for electrophoresis, ≥99% (HPLC), powder
Supelco
Dodecilsulfatosódico, dust-free pellets, suitable for electrophoresis, for molecular biology, ≥99.0% (GC)
Sigma-Aldrich
Dodecilsulfatosódico, BioXtra, ≥99.0% (GC)
Sigma-Aldrich
Dodecilsulfatosódico, ≥98.0% (GC)
Sigma-Aldrich
Dodecilsulfatosódico, 92.5-100.5% based on total alkyl sulfate content basis
Sigma-Aldrich
Dodecilsulfatosódico, tested according to NF, mixture of sodium alkyl sulfates consisting mainly of sodium dodecyl sulfate
Sigma-Aldrich
Dodecilsulfatosódico, ≥90% ((Assay))
Sigma-Aldrich
Bicinchoninic acid disodium salt hydrate, ≥98% (HPLC)
Sigma-Aldrich
Dodecilsulfatosódico, BioReagent, suitable for electrophoresis, for molecular biology, ≥98.5% (GC), free-flowing, Redi-Dri
Sigma-Aldrich
MISSION® esiRNA, targeting human DNMT1
Sigma-Aldrich
MISSION® esiRNA, targeting mouse Dnmt1